TL;DR
MOTS-c is a 16-amino acid peptide encoded by mitochondrial 12S rRNA — the first known mitochondria-to-nucleus signaling peptide. It acts as a mitokine that mimics the metabolic benefits of exercise and methionine restriction without requiring either. Core mechanism: inhibits the folate cycle → 20× AICAR accumulation → AMPK activation → epigenetic reprogramming. Animal data: 6.4% lifespan extension, 2× running performance restoration in aged mice, myostatin inhibition for muscle preservation, β-cell senescence prevention. Banned by WADA 2025 and restricted by FDA Category 2. Research-only.
Why it matters for Vitals
- Exercise mimetic mechanism (AMPK activation) maps to wearable HRV/sleep/HR signatures — similar adaptive stress response to physical training
- Myostatin inhibition directly addresses the lean mass preservation problem in GLP-1 protocols — relevant stack partner for Retatrutide
- Short half-life (<2 hrs) means frequent dosing — community practice diverges significantly from animal HED; wearable tracking can help calibrate
- WADA ban means athletes need to know detection risk
Key Facts
| Status | Research-only; FDA Category 2 (prohibited for compounding); WADA-banned 2025 (S4) |
| Class | Mitochondrial-derived peptide (MDP) / mitokine / exercise mimetic |
| Core mechanism | Folate cycle inhibition → 20× AICAR → AMPK activation (Thr172) + CK2-PTEN-mTORC2-AKT-FOXO1 → myostatin inhibition |
| Key animal outcomes | 6.4% lifespan extension; 2× running performance in old mice; myostatin inhibition; β-cell senescence prevention (SNU 2025) |
| Dosing | SubQ/IM only (zero oral); community practice 5–10 mg, 3–7×/wk — well below mouse HED (~28–85 mg) |
| Main risks | Research chemical with no approved human dose; sterility of source is primary practical risk; WADA detection |
| Evidence level | Strong preclinical (lifespan, metabolic, exercise); limited human data (CB4211 trial discontinued) |
Mechanism Summary
Folate-AICAR-AMPK Axis (Core)
MOTS-c → folate cycle inhibition → 5Me-THF depletion
↓
AICAR accumulation (20×)
↓
AMPK activation (Thr172)
↓
Nuclear translocation → epigenetic reprogramming
- Methionine restriction = established longevity intervention (up to 45% lifespan extension in rodents)
- MOTS-c achieves this biochemically without dietary restriction — mTORC1 inhibition → SASP suppression
- AMPK activation also triggers GLUT4 translocation (insulin-independent glucose uptake), fatty acid oxidation, mitochondrial biogenesis
Myostatin Inhibition
Via CK2-PTEN-mTORC2-AKT-FOXO1 pathway:
- Prevents palmitic acid-induced muscle atrophy
- Direct anti-sarcopenia mechanism distinct from GH/IGF-1 axis
- Relevant for countering lean mass loss during GLP-1 agonist protocols
NRG1-ErbB4 (Cardiovascular)
Exercise-like cardioprotection via neuregulin signaling — restores cardiac OXPHOS, reduces LV wall thickness.
β-Cell Senescence Prevention (2025 SNU)
Prevents/reverses β-cell senescence (p16, p21, γ-H2AX suppression) → improved glucose tolerance — metabolic longevity signal.
What the current evidence suggests
- Lifespan (mice): 6.4% median extension with late-life intervention (24–27 months); 65% hazard reduction
- Exercise performance (mice): 2× running time and distance in old mice (22 months); human muscle shows 11.9× increase post-exercise
- Myostatin (preclinical): Palmitic acid-induced atrophy blocked via FOXO1 pathway
- β-cells (2025 SNU): Senescence markers suppressed; glucose tolerance improved
- Human translation gap: Phase 1a/1b CB4211 trial (CohBar) completed but program discontinued; injection site reactions limited efficacy; practical community dosing far below animal HED
- Confidence level: High for animal data; low-moderate for human translation (no approved dose, no long-term human safety data)
Risks and Uncertainty
| Risk | Detail |
|---|---|
| No approved human dose | HED from mice is 28–85 mg; community practice is 5–10 mg — significant underexposure vs animal models |
| WADA ban | Detectable at 100 pg/mL via LC-MS; banned in competitive athletes |
| FDA Category 2 | Prohibited for compounding in the US |
| Sterility risk | Primary practical risk — sourcing quality is the real-world variable |
| Short half-life | <2 hours requires frequent injection; compliance challenge |
| CB4211 discontinued | No commercial development path visible |
| Confidence level | High preclinical; low-moderate human (dose, safety, long-term outcomes unknown) |
Best Stack Context
| Partner | Rationale |
|---|---|
| NMN NAD+ | Dual-axis AMPK activation: MOTS-c (direct AICAR) + NMN/NR (indirect SIRT1/LKB1) |
| Retatrutide | GLP-1 drives fat loss; MOTS-c protects muscle (myostatin inhibition) — counter sarcopenia |
| SLU-PP-332 | MOTS-c = stress response (AMPK); SLU-PP-332 = structural adaptation (ERRα/PGC-1α); together: bigger engine + optimized fuel |
| BPC-157 | BPC-157 is ATP-hungry (tissue repair); MOTS-c boosts ATP generation; builder + power source |
| Wn561 | Both AMPK-activated metabolic optimizers; complementary pathways |
Comparison to Related Compounds
| Compound | Mechanism | vs MOTS-c |
|---|---|---|
| SLU-PP-332 | ERRα agonism → PGC-1α mitochondrial biogenesis | MOTS-c is AMPK-first; SLU-PP is ERR-first — complementary |
| Retatrutide | GLP-1/GIP/Glucagon triple agonism | MOTS-c is peripheral AMPK/myostatin; GLP-1 is central appetite |
| NMN NAD+ | NAD+ → SIRT1 → LKB1 → AMPK (indirect) | Both converge on AMPK; MOTS-c is direct, NMN is upstream |
| Humanin | MDP; 16S rRNA; receptor FPRL1 | MOTS-c is 12S rRNA; different mechanism and cell target |
Links
- Peptides MOC
- SLU-PP-332 — complementary exercise mimetic (ERR vs AMPK)
- Retatrutide — anti-sarcopenia stack
- NMN NAD+ — dual AMPK activation
- BPC-157 — ATP synergy
- Exercise Mimetics — shared mechanism class
Source: USC / Seoul National University · Nature Communications · Aging Cell · SNU 2025 β-cell study · CohBar CB4211 · FDA/WADA status 2025